Radiopharmaceutical therapy is rapidly reshaping the treatment landscape for advanced prostate cancer. At the 2026 ASTRO Radiopharmaceutical Symposium, investigators presented, in a plenary session, a pooled analysis of randomized Phase II and III trials evaluating 177Lu-PSMA-617, a targeted radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC). The findings offer important clarity on efficacy, safety, and clinical positioning, while also highlighting the growing role of multidisciplinary infrastructure in delivering this therapy effectively.

The data were presented by Mohammad Arfat Ganiyani, M.D., MBBS, research associate under the mentorship of Rohan Garje, M.D., Chief of Genitourinary Medical Oncology at Baptist Health Miami Cancer Institute, underscoring the Institute’s leadership in advancing radiopharmaceutical research and clinical application.

“Across randomized data, this therapy consistently delays disease progression and is generally well tolerated, but it requires thoughtful patient selection and careful monitoring,” said Dr. Garje. “The real-world impact is greatest when it is delivered within a coordinated, multidisciplinary setting.”

A Consistent Signal: Delayed Disease Progression

The pooled analysis synthesized data from seven randomized trials, encompassing more than 2,500 patients, to evaluate outcomes associated with 177Lu-PSMA-617. By aggregating evidence from landmark studies, investigators achieved greater statistical power than any single trial could provide.

The most consistent and clinically meaningful finding was a significant improvement in progression-free survival (PFS). The pooled hazard ratio of 0.64 corresponds to a 36 percent relative reduction in the risk of disease progression, reinforcing the role of PSMA-targeted radioligand therapy as an effective disease-control strategy across multiple treatment settings. While individual trials have previously demonstrated benefit, this meta-analysis strengthens confidence in the reproducibility of that effect across diverse patient populations and therapeutic contexts.

Interpreting the Overall Survival Signal

In contrast to PFS, the pooled analysis did not demonstrate a consistent overall survival (OS) benefit. However, this finding requires careful interpretation. Differences in trial design likely contributed to the variability in OS outcomes. These include heterogeneity in control arms, variation in prior lines of therapy, and differences in disease burden at baseline. Additionally, crossover and access to effective post-progression therapies can dilute survival differences between study arms.

Importantly, prior pivotal trials have demonstrated an OS benefit in specific populations. The pooled analysis does not negate those findings but rather underscores that OS is more difficult to standardize across heterogeneous trials, particularly when subsequent

therapies influence outcomes. As Dr. Garje explained in presenting the data at ASTRO, “the most consistent signal we see across trials is a progression-free survival benefit, while overall survival is often influenced by trial design, sequencing, and access to subsequent therapies.”

For clinicians, the takeaway is clear: 177Lu-PSMA-617 has a robust and consistent impact on delaying progression, while survival outcomes remain context-dependent.

Safety and Delivery in Practice

The analysis also provides important insights into safety. The most notable adverse event associated with ¹??Lu-PSMA-617 is hematologic toxicity, particularly thrombocytopenia. The pooled risk ratio of 5.79 highlights a significantly increased risk compared to control therapies. This finding reinforces the need for careful baseline marrow assessment, ongoing laboratory monitoring, and coordinated management of hematologic adverse events.

“Radioligand therapy is highly targeted, but it is not without risk,” Dr. Garje noted. “Hematologic toxicity, particularly thrombocytopenia, requires proactive monitoring and close coordination across the care team to ensure patient safety.”

Despite these risks, the therapy is generally well tolerated when delivered within experienced centers that can provide structured follow-up and multidisciplinary oversight. Radiopharmaceutical therapy is not a plug-and-play intervention. It requires specialized infrastructure, including PSMA-PET imaging, nuclear medicine capabilities, and close coordination between medical oncology and radiation oncology.

At Miami Cancer Institute, this integrated approach has enabled optimized patient selection and proactive toxicity management. Patients benefit from seamless coordination across specialties, ensuring that treatment decisions are individualized and evidence-based. This model also enhances adherence to treatment and monitoring protocols, which is critical given the need for repeated dosing and follow-up evaluations.

Expanding Access and Looking Ahead

Access remains a critical factor in the real-world impact of radiopharmaceutical therapy. For patients with advanced prostate cancer, the burden of travel can be substantial, particularly when treatment requires multiple visits. Providing 177Lu-PSMA-617 locally within South Florida significantly reduces logistical and financial barriers. It also improves continuity of care, allowing patients to remain within a familiar healthcare system while receiving highly specialized treatment.

Participation in multicenter trials has been instrumental in advancing the field and elevating patient care. By contributing to trial design, data analysis, and scientific presentation, institutions such as MCI are helping define how radiopharmaceutical therapies are evaluated and implemented. Trial participation also provides patients with early access to cutting-edge therapies and ensures that care is delivered according to rigorous, standardized protocols.

As with any meta-analysis, limitations must be acknowledged. The pooled trials differed in patient populations, treatment sequencing, comparator therapies, and definitions of progression and toxicity. These sources of heterogeneity introduce variability that can affect interpretation.

Looking ahead, several key research priorities remain: refining patient selection using advanced imaging and biomarker thresholds; determining optimal sequencing relative to androgen receptor pathway inhibitors, chemotherapy, and other systemic therapies; exploring combination strategies with radiosensitizers or DNA damage response agents; and improving dosimetry and personalization of treatment. For clinicians, the evolving evidence base for ¹??Lu-PSMA-617 reinforces a broader shift toward precision oncology. By delivering targeted radiation directly to tumor cells, radioligand therapy represents a convergence of diagnostics and therapeutics, often described as theranostics.

As access expands and evidence continues to mature, 177Lu-PSMA-617 is poised to become an increasingly central component of care for patients with advanced prostate cancer. The challenge, and the opportunity, lies in integrating this innovation into multidisciplinary, patient-centered care models that can deliver its full benefit.